Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...

Background: To identify differences between Ranibizumab and Aflibercept in treatment-naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting ...

Brolucizumab is a follow-up to Novartis’ blockbuster AMD therapy Lucentis (ranibizumab), which has been competing toe-to-toe in the AMD market with Eylea for several years. Novartis reported ...

and compared Eylea versus Novartis' rival treatment Lucentis, and Roche's Avastin. The trial came about because of extensive off-label prescribing of Avastin against eye diseases such as age ...

Opthea (ASX:OPT) has announced that its lead drug candidate sozinibercept has failed to meet primary endpoints in a phase 3 ...

Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12. The firm cites the company ...

But in 2004, a groundbreaking new treatment called anti-VEGF—including drugs such as Lucentis, Eylea, and Avastin—became available. These drugs work to stop the blood vessels from growing ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary endpoint and the only time stamp out of 10 in which the candidate ...